Update on safety and feasibility of the combination of pembrolizumab and pelvic chemoradiation in locally advanced cervical cancer

Documenti analoghi

• Top advances of the year: Cervical cancer
  di: Linda R. Duska, et al.
  Pubblicazione: (2024)
• Biopsy‐proven residual cervical cancer at the end of combined chemoradiation predicts poor outcome—Retrospective single‐center cohort study
  di: Christoph Ebner, et al.
  Pubblicazione: (2025)
• Integrated genomic and proteomic profiling reveals insights into chemoradiation resistance in cervical cancer
  di: Janani Sambath, et al.
  Pubblicazione: (2026)
• Overall survival benefit of pembrolizumab plus chemoradiotherapy for patients with high‐risk locally advanced cervical cancer
  di: Mary Beth Nierengarten
  Pubblicazione: (2025)
• A phase 1b/2 study of cabozantinib in combination with pembrolizumab in advanced cutaneous melanoma
  di: Yousef Zakharia, et al.
  Pubblicazione: (2026)